Emtricitabine And Tenofovir Disoproxil Fumarate Tablet, Film Coated
NDC Package 70771-1621-9
Package Information
Emtricitabine And Tenofovir Disoproxil Fumarate tablets is classified as a
- hepatitis b virus nucleoside analog reverse transcriptase inhibitor - [epc] (established pharmacologic class)
- human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor - [epc] (established pharmacologic class)
- nucleoside reverse transcriptase inhibitors - [moa] (mechanism of action)
- nucleosides - [cs]
Identification & Billing
- RxCUI: 1744001 - emtricitabine 100 MG / tenofovir disoproxil fumarate 150 MG Oral Tablet
- RxCUI: 1744001 - emtricitabine 100 MG / tenofovir disoproxil fumarate 150 MG (equivalent to tenofovir disoproxil 123 MG) Oral Tablet
- RxCUI: 1744005 - emtricitabine 133 MG / tenofovir disoproxil fumarate 200 MG Oral Tablet
- RxCUI: 1744005 - emtricitabine 133 MG / tenofovir disoproxil fumarate 200 MG (equivalent to tenofovir disoproxil 163 MG) Oral Tablet
- RxCUI: 1744009 - emtricitabine 167 MG / tenofovir disoproxil fumarate 250 MG Oral Tablet
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 70771 - Zydus Lifesciences Limited
- 70771-1621 - Emtricitabine And Tenofovir Disoproxil Fumarate
- 70771-1621-9 - 90 TABLET, FILM COATED in 1 BOTTLE
- 70771-1621 - Emtricitabine And Tenofovir Disoproxil Fumarate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70771-1621). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70771-1621-9 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Emtricitabine And Tenofovir Disoproxil Fumarate, a human prescription drug labeled by Zydus Lifesciences Limited. This tablet, film coated is formulated for oral use and contains emtricitabine; tenofovir disoproxil fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on July 01, 2021. The current certification is valid through December 31, 2026.
How is this Zydus Lifesciences Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771162109. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.